Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations (UPLIFT)
A Randomized, Phase III Umbrella Trial of Adjuvant Therapy Versus Observation in Completely Resected High-Risk Stage IA-IB Non-Small Cell Lung Cancer Based on Oncogenic Driver Mutations
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-75 years and able to provide written informed consent.
- Primary non-squamous NSCLC confirmed by pathology, with no brain metastases.
- Complete R0 surgical resection (lobectomy, segmentectomy, or pneumonectomy) of stage IA or IB NSCLC (AJCC 8th edition).
- High-risk disease (one or more): low differentiation, solid/micropapillary/complex glandular patterns, vascular invasion, visceral pleural invasion, alveolar space spread, or intermediate/high risk on 14-gene test.
- Documented driver gene status (EGFR mutation, ALK/ROS1 fusion, or wild-type) via postoperative tumor sample.
- ECOG performance status 0 or 1, with stable condition over the last two weeks.
- Surgery within 4-10 weeks before starting treatment, with full recovery.
- Adequate organ function as per protocol-defined labs.
- Negative pregnancy test (if applicable) and use of effective contraception during and 3 months after treatment.
Exclusion Criteria:
- Evidence of unresectable/metastatic NSCLC, incomplete resection (R1/R2), or wedge resection only.
- Prior systemic therapy (e.g., chemotherapy, targeted therapy, immunotherapy) for the current NSCLC.
- Major surgery (excluding lung cancer surgery) within 3 weeks before first study dose.
- Planned concurrent anti-cancer therapy (chemo, radiotherapy, or targeted therapy) during the study.
- Clinically significant cardiac disorders (e.g., poorly controlled hypertension, recent MI or stroke, prolonged QTc).
- History or suspicion of interstitial lung disease requiring treatment.
- Active or uncontrolled infection (e.g., hepatitis B with detectable HBV DNA, hepatitis C, HIV, active TB).
- Severe GI conditions impairing drug absorption (e.g., Crohn's, ulcerative colitis).
- Use of strong CYP3A inducers/inhibitors within 1 week or ongoing need for warfarin.
- Participation in another interventional trial within 4 weeks or receipt of a live vaccine within 180 days.
- Any condition that may compromise adherence or safety, per investigator judgment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Observation
|
|
|
Experimental: Adjuvant therapy
|
Oral icotinib tablets (125 mg) administered three times daily (TID) for up to 1 year or until disease recurrence or unacceptable toxicity.
Icotinib is an EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing mutations.
Oral rezivertinib capsules (100 mg) taken once daily (QD) for up to 1 year or until disease recurrence or unacceptable toxicity.
Rezivertinib is an EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing mutations.
Oral ensartinib capsules (225 mg) taken once daily (QD) for up to 1 year or until disease recurrence or unacceptable toxicity.
Ensartinib is an ALK/ROS1 tyrosine kinase inhibitor designed to inhibit ALK/ROS1 fusion-driven NSCLC.
Intravenous infusion of bemosumab 1200 mg every 3 weeks (Q3W).
Treatment continues for up to 4 cycles initially, and may be extended (maintenance) for up to 3 years or until disease recurrence or unacceptable toxicity.
Bemosumab is a monoclonal antibody under investigation for immunotherapy in NSCLC.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease-Free Survival (DFS)
Time Frame: From randomization until disease recurrence or death (up to approximately 5 years)
|
Disease-free survival (DFS) is defined as the time from randomization to the first documented disease recurrence (local relapse or distant metastasis confirmed by imaging or pathology) or death from any cause, whichever occurs first.
Participants without documented recurrence or death at the time of analysis will be censored at their last disease assessment date.
|
From randomization until disease recurrence or death (up to approximately 5 years)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival (OS)
Time Frame: From randomization to death or last follow-up (up to approximately 5 years)
|
Overall survival (OS) is defined as the time from randomization to death from any cause.
Participants who remain alive or are lost to follow-up at the time of analysis will be censored at the date of last contact.
|
From randomization to death or last follow-up (up to approximately 5 years)
|
|
Central Nervous System Disease-Free Survival (CNS DFS)
Time Frame: From randomization until CNS progression or death, whichever occurs first (up to approximately 5 years)
|
CNS DFS is defined as the time from randomization to the date of first occurrence of central nervous system (CNS) metastases or death from any cause, whichever occurs first, as determined by imaging or clinical assessment.
Participants without a CNS event or death at the time of analysis will be censored at their last disease assessment date.
|
From randomization until CNS progression or death, whichever occurs first (up to approximately 5 years)
|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: From date of randomization up to approximately 5 years
|
AEs graded by CTCAE version 5.0
|
From date of randomization up to approximately 5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Antineoplastic Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Ensartinib
Other Study ID Numbers
Other Study ID Numbers
- UPLIFT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.